Skip to main content
. 2015 May 5;6:91. doi: 10.3389/fneur.2015.00091

Table 1.

Patient demographic and baseline characteristics – discovery cohort.

PD (n = 36) MSA (n = 27) Controls (n = 57)
Age in years (SD)b 60.1 (10.4) 62.6 (9.0) 57.0 (11.5)
Number of males (%) 22 (61.1) 15 (55.6) 37 (64.9)
Years of follow-up (range) 5.5 (0–9.2) 2.9 (0–7.9) N/A
NFL (ng/L) 1350 (915) 4548 (3206) 1503 (619)
FLT3L (ng/L) 38.4 (11.9) 39.3 (12.4) 47.8 (14.3)
t-tau (ng/L) 242 (190) 335 (164) 251 (110)
Disease duration, months (range)c PD (n = 28) MSA (n = 14) p-Valuea
43.8 (6–158) 43.7 (8–96) p = 0.508
Disease severityc PD (n = 32) MSA (n = 14) p-Valuea
H&Y 2.0 (0.60); n = 32 2.7 (1.2); n = 14 p = 0.014
UPDRS; mean (SD) 30.3 (11.5); n = 27 32.5 (16.7); n = 14 p = 0.627
ICARS; mean (SD) 2.9 (4.8); n = 20 12.1 (9.5); n = 9 p = 0.020
Cognitive function PD (n = 28) MSA (n = 14) p-Valuea
MMSE; mean (SD) 28.5 (1.6) 27.5 (3.5) p > 0.05

SD, standard deviation; H&Y, Hoehn and Yahr score; ICARS, International Cooperative Ataxia Rating Scale; UPDRS, unified Parkinson’s disease rating scale; N/A, not applicable.

aStudent’s t-test p-values for PD versus MSA.

bAt time of lumbar puncture.

cAt time of inclusion.